ASIT biotech significantly moves forward in the preparation of the clinical development plan of gp-ASIT+TM in the US
(WorldNews Belgium)

Regulated information ASIT biotech significantly moves forward in the preparation of the clinical development plan of gp-ASIT+TMin the US Brussels, Belgium, December 6, 2017, 7 am (CET)-ASIT biotech (Euronext: ASIT - BE0974289218), a Belgian clinical-stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, has made significant progress in the preparation of the clinical development, in the United States, of gp-ASIT+TM, its lead drug candidate for the treatment of grass pollen rhinitis. ASIT biotech has received positive feedback from the US Food and Drug Administration (FDA) on the...